Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fanapt for Uncontrolled Hypertension
NCT07090161Phase 2Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iloperidone in hypertension (HTN), sponsored by Vanda Pharmaceuticals Inc.. Started Sep 2025; status: recruiting.
02
Drugs
iloperidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07090161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090161.